In June 2025, the Indian Ministry of Health and Family Welfare implemented new guidelines for the export of over-the-counter (OTC) pharmaceutical products, including "Moov." These guidelines aim to streamline the export process and ensure compliance with international standards.
In September 2025, the Directorate General of Foreign Trade (DGFT) introduced an online portal for the issuance of No Objection Certificates (NOCs) required for pharmaceutical exports. This digital initiative is designed to expedite the approval process and enhance transparency.
In December 2025, the Central Drugs Standard Control Organisation (CDSCO) updated the Indian Pharmacopoeia to include revised standards for topical analgesic products. Manufacturers of products like "Moov" are required to comply with these updated standards to ensure product quality and safety.
In February 2026, the National Pharmaceutical Pricing Authority (NPPA) conducted a review of the pricing of non-scheduled drugs, including OTC products. While "Moov" remains outside the purview of price control under the DPCO, the NPPA emphasized the importance of fair pricing practices in the pharmaceutical industry.
In March 2026, the World Health Organization (WHO) released a report highlighting the significance of adhering to international pharmacopoeia standards for OTC products. The report underscores the need for manufacturers to ensure their products meet these standards to facilitate global trade and maintain consumer trust.
